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This review is of a series of the authors' studies designed to test the hypothesis that
administration of trichloroethylene (TCE), dichloroethylene (DCE), their metabolites, and related
compounds are responsible for fetal cardiac teratogenesis when given to pregnant rats during
organogenesis. Identification of teratogenic compounds will allow more accurate assessment of
environmental contaminants and public health risks. Epidemiologic studies and previous
teratogenic studies using chick embryos and fetal rats have reported an increased number of
congenital cardiac defects when exposed to TCE or DCE during fetal development. Metabolites of
TCE and DCE studied in the drinking-water exposure study include trichloroacetic acid (TCAA),
monochloroacetic acid, trichloroethanol, carboxymethylcysteine, trichloroacetaldehyde,
dichloroacetaldehyde, and dichlorovinyl cysteine. Varying doses of each were given in drinking
water to pregnant rats during the period of fetal heart development. Rats receiving 2730 ppm
TCAA in drinking water were the only metabolite group demonstrating a significant increase in the
number of cardiac defects in fetuses on a per-litter basis (p=0.0004 Wilcoxon test and p=0.0015
exact permutation test). Maternal and fetal variables showed no statistically significant differences
between treated and untreated groups. When treated with TCAA the increased cardiac defects, as
compared to controls, do not preclude the involvement of other metabolites as cardiac teratogens,
but indicates TCAA as a specific cardiac teratogen. Further studies of drinking-water exposure and
potential mechanisms of action on the developing heart are proceeding. Environ Health
Perspect 106(Suppl 4):995-999 (1998). http://ehpnetl.niehs.nih.gov/docs/1998/Suppl-4/
995-999johnson/abstract.html
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Introduction
Halogenated hydrocarbons such as
trichloroethylene (TCE), and its metabolic
products, are among the most common
water supply contaminants in the United
States and around the world (1). Also,
in the presence of natural organic mater-
ial, chlorination of municipal water to
eliminate coliform bacteria produces a
number of quantitatively important
chlorinated organic compounds including
the TCE metabolites chloral hydrate
(TCAld), trichloroacetic acid (TCAA), and
dichloroacetic acid (DCAA) (2-4). The
U.S. population consumes chlorinated
drinking water, which is a major source of
ingestion of these chlorinated organic
compounds (5). Thus, both contaminated
water and municipal water are both
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potential sources ofexposure to TCE and
its metabolites.
A previous epidemiologic study in Santa
Clara, California, by Swan et al. (6) also
found an association between these halo-
genated hydrocarbons and increased inci-
dence of major cardiac malformations in
children born to mothers who lived in areas
ofwater contamination. Shaw et al. (7) cor-
related the presence ofbirth defects in the
San Francisco Bay area in California with
the level ofindustrial pollutants by census
tract and found an elevation in the risk that
infants would be born with malformations
ofthe heart and circulatory system (relative
risk= 1.5), even though birth weight (often
a reliable index ofgeneral fetal toxicity) was
not related to pollution levels (7).
An epidemiologic study in the
Southwestern United States found an asso-
ciation between the presence ofTCE and
dichloroethylene (DCE) in contaminated
water and an increased incidence ofmajor
cardiac malformations in children born to
mothers residing in contaminated areas
(8). Although this case-control study
demonstrated an association between the
halogenated hydrocarbon contaminants
and congenital heart defects, it was not
designed to establish a cause and effect
relationship. As a result, in vivo studies
were undertaken to determine the possible
teratogenicity ofTCE and DCE in both
avian and rat models.
Avian studies (9,10) demonstrated that
TCE and DCE had both general and car-
diac teratogenic effects on the developing
chick. Subsequent controlled studies in the
pregnant rat model (11,12) determined a
significantly increased frequency ofcardiac
defects in fetuses, as compared to controls,
after direct intrauterine exposure to TCE
and DCE. Compounds were then adminis-
tered to the dam in drinking water during
the critical days of fetal organogenesis to
more closely simulate human exposure
conditions. Similar significant increases in
cardiac defects were observed. Other
researchers have studied chlorinated hydro-
carbon effects and those that studied the
heart also demonstrated a significant
increased frequency of congenital cardiac
malformations (13-21). A recent study of
whole-embryo exposure to TCE and other
related compounds (including metabolites)
demonstrated embryotoxicity and various
developmental abnormalities (22).
Our objective was to determine whether
the parent compounds (TCE or DCE) or
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one or more oftheir metabolites showed
increased numbers ofcardiac defects in fetal
rats, as compared to controls, when the
pregnant rats were exposed via drinking
water. Metabolites tested included TCAA,
monochloroacetic acid (MCAA), tri-
chloroethanol (TCEth), carboxymethylcys-
teine (CMC), TCAld, dichloroacetaldehyde
(DCAld), and dichlorovinyl cysteine
(DCVC). Based on work by others, the
most suspect metabolites were weak acids
such as TCAA or MCAA or an alcohol
such as TCEth (4,13-22).
The initial concentration selection was
based on the level ofthe maximum solubil-
ity ofTCE (1100 ppm). This was consid-
ered the high level, and a concentration
level ofapproximately 1000-fold less was
used as a low exposure level (1.5 ppm
TCE). The animals were initially given the
drinking water during pregnancy and
prepregnancyand pregnancyalone to deter-
mine if the timing of the ingestion was
related to an effect on the heart. The high
concentration of DCE (110 ppm DCE)
was given in proportion to the levels found
in the closed Tucson, Arizona, wells (100-
foldless than TCE) (23). Again, an approx-
imately 1000-fold lower dose was used as
the low dose (0.15 ppm DCE). The initial
metabolite concentration selection was
based on the maximum level ofthe metabo-
lite that would be expected to be produced
from breakdown ofthe maximum solubility
level of TCE tested (1100 ppm TCE).
These concentrations were chosen as initial
provocative screening levels, and depending
on the results other concentrations may be
tested. The concentration (the amount of
compound in the drinking water solution)
was initially used for reporting because of
its ease in comparing to levels found in the
contaminated drinking water wells. For
comparison with other studies, we con-
verted the levels of concentration into a
dose level using the amount consumed per
day, the number ofdays consumed, and the
average weight ofthe rat during the treat-
ment period. Table 1 contains concentra-
tion and corresponding dose levels for
TCE, DCE, and the metabolites studied.
All studies using animals were conducted
in accordance with guidelines established by
the Animal Welfare Act (24) and in the
University ofArizona's approved Association
for Assessment and Accreditation of
LaboratoryAnimal Care-accredited facilities.
Review of Study Results
The following review is acompilation ofthe
drinking water studies performed by this
Table 1. Concentration versus average dosage consumed.
Drinking waterdosage
Normal
TCE
TCE
DCE
DCE
TCAA
MCAA
TCEth
TCAld
DCAld
CMC
DCVC
Concentration, ppm
Water
1100
1.5
110
0.15
2730
1570
1249
1232
174
473
50
laboratory (12,25). Data were compiled
for treatment groups ofall compounds and
included maternal observations, in situ
uterine abnormalities, fetal observations,
types ofcardiac anomalies, and percent of
congenital fetal cardiac anomalies calcu-
lated both on a per-fetus basis and a per-
litter basis. The results are given in Figure 1
andTable 2.
MatemalObservations
Maternal observations included weight
gain, pregnancy complications, and uter-
ine examination. All maternal rats in
the TCE, DCE, and metabolite studies
were healthy, with steady weight gain,
throughout the study and without evi-
dence of toxicity. There were no preg-
nancy complications, and at termination,
all uterine and ovarian morphologic
examinations were normal.
InSituUterineAbnormalites
Uterine examination included inspection
for implantation sites (sites of initial
attachment of a fertilized ovum, but with
no further growth, leaving a yellowish tis-
sue site), resorption sites (sites ofimplanta-
tion with embryonic growth but arrest and
necrosis during development as evidenced
by the necrotic embryonic tissue that
remains), and external inspection of live
and dead fetuses. Using Fisher exact analy-
sis, no differences were found between
treated groups and controls for the mean
number of implantation sites and resorp-
tion sites except for the TCAA group, in
which a significant increase occurred (1.1
average implantation sites per litter
[p=0.0006] for TCAA exposure, as com-
pared to 0.20 average implantation sites/
litter for controls and 2.7 average resorp-
tion sites/litter [p= 0.0001] TCAA, as
compared to 0.70 average resorption sites
per litter for controls).
Equivalent dosage,
mg/kg/day
N/A
129
0.218
10.64
0.015
291
193
153
151
21
58
6
Average
mi/day/rat
46
45
57
38
38
38
21
53
42
55
55
40
Fetal Observations
Fetal observations and measurements
included numbers oflive or dead fetuses,
fetal weight, placental weight, crown-rump
length, and external morphology. No sig-
nificant difference was found when com-
paring treated and control fetal groups for
these observations. There were no gross
external or noncardiac internal organ con-
genital abnormalities found in any treated
or control groups.
CaidiacAnomalies
Although several different cardiac
malformations were found in the metabo-
lite exposures, no one lesion or grouping
predominated. Fetuses exposed to TCE
and DCE had cardiac defects thatwere also
diverse and demonstrated no grouping.
Cardiac defects in the metabolite study
were grouped in general categories and
listed by treatment in Table 2. Variations
of normal morphology similar to those
found in humans were not classified as
defects (for example, tricuspid valve leaflet
contribution to complete coverage of a
membranous ventricular defect). Defects in
the metabolite study group were as follows:
secundum type atrial septal defects (n= 16);
hypoplasia ofthe aorta or pulmonary artery
(n= 9); aortic valve defects with fused
leaflets (bicuspid or tricuspid) creating aor-
tic valvular stenosis (n = 2); pulmonary
valve stenosis (n=6), including hypoplastic
annulus and leaflet adhesions; hypoplastic
mitral valve annulus (n=6); tricuspid valve
defects (n= 1); abnormal looping (n=2);
atrioventricular septal defect (n= 1); and
both perimembranous (n= 10) and muscular
(n=8) ventricular septal defects. A nearly
equal proportion ofdefects was demon-
strated when the defects were divided into
left and right heart abnormalities: 11 left-
sided versus 13 right-sided defects. Septation
defects appear to be more represented than a
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Figure 1. Percent of abnormal hearts (fetal basis). Abbreviations: p+ p, prepregnancy and pregnancy exposure; p, pregnancy-only exposure. *Statistical significance between
the treated and control group.
Table2. Congenital cardiac malformations.
Group
Normal TCE p+p, TCE p+p, TCE p, DCE p+p, DCE p+p, TCAA p, MCAA p, TCEth p, TCAld p, DCAld p, CMC p, DCVC p,
Heartabnormalities water 1100 ppm 1.5ppm 110ppm 11Oppm 0.15ppm 2730ppm 1570ppm 1249ppm 1232ppm 174ppm 473ppm 50ppm
Abnormal looping 2 - 2 - - - - - - - - - -
Aortic hypoplasia - 1 1 - 1 - 1 - 1 - 1 - 1
Pulmonaryartery - - 1 - - - 2 1 - - 2 -
hypoplasia
Atrial septal defects 7 19 5 7 11 7 3 3 - 2 - - 1
Mitral valve defects, 1 5 8 - 4 3 1 - 1 2 - - 1
hypoplasia or ectasia
Tricuspid valve defects, - 1 1 - 1 - - - 1 - -
hypoplasia orectasia
Ventricular septal defects
Perimembranousa 2 6 2 1 4 1 4 - - 3 - 1 -
Muscular 2 4 - 4 2 1 1 - 1 - - 2 2
Atrioventricular 1 - - 1 1 - - - - - - -
septal defects
Pulmonaryvalve defects - 2 1 - 1 - 1 3 1 1 - - -
Aorticvalve defects - 2 2 2 2 3 - - 1 - 1
Situs inversus - 1 - - - - - - - - - - -
Total
Abnormal hearts 15 41 23 15 25 15 13 7 6 8 3 4 5
Fetuses with 13 40* 22* 11* 24* 14* 12* 6 5 8 3 4 5
abnormal hearts
Fetuses 605 434 255 105 184 121 114 132 121 248 101 85 140
aSubaortic. *Per-fetus statistical significance (Fisher exactanalysis).
difference between lesions of the left and
right sides ofthe heart.
Percent ofCongenital Fetal
CardiacAnomalies
In our initial studies, which involved admin-
istering TCE and other compounds in utero
via an intrauterine osmotic mini-pump
(Alzet Corp., Inc., Palo Alto, CA), the mem-
bers of a litter were not necessarily exposed
equally to the compounds, as delivery was
not related to maternal metabolism. On the
recommendations of a biostatistician, these
cases were statistically analyzed on a per-
litter and per-fetus basis.
The previous study on TCE and DCE
in drinking water examined over 1800 fetal
rat hearts with a variety of exposure times
during prepregnancy and pregnancy. The
1 100 and 1.5 ppm TCE prepregnancy +
pregnancy exposure groups and the 1 100
ppm TCE pregnancy-only group had a
significantly increased number of fetal
cardiac defects when compared to controls
(Figure 1) on a per-fetus and per-litter
basis. The groups tested under prepreg-
nancy only showed no statistical signifi-
cance when compared to controls. Because
the initial studies ofTCE exposure during
prepregnancy + pregnancy and pregnancy
only demonstrated similar outcomes, it was
decided to test DCE only in the prepreg-
nancy and prepregnancy + pregnancy
exposures to determine if pregnancy was
the vulnerable stage and prepregnancy
exposure had no effect. Similar to the TCE
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exposures, both the 110 and 0.15 ppm
DCE prepregnancy +pregnancy exposure
groups demonstrated significantly
increased numbers of fetal cardiac defects
when compared to controls, whereas the
prepregnancy-only exposures did not.
In the metabolite study 605 control fetal
hearts and 941 treated fetal hearts (divided
into seven groups) were examined (Figure
1). Examination ofthe fetuses on an indi-
vidual basis made the assumption that each
fetus has an equal chance ofdeveloping a
heart malformation independent ofits litter-
mates. Fetal hearts were also evaluated on a
per-litter basis. Cardiac abnormalities per
group ranged from 2.97 to 10.53%, with a
control group value of2.15%. The 2730
ppm TCAA (291 mg/kg/day) during preg-
nancy group had 10.53% abnormal hearts
from a total of 114 fetuses. The malforma-
tion rate for the TCAA group was signifi-
cantly greater than controls on a per-fetus
basis (p=0.0001, Fisher exact test) and a
per-litter basis [Wilcoxon and exact permu-
tation tests, p= 0.0004 and p= 0.0015,
respectively (26)]. As compared to controls,
no other group demonstrated a significant
increase in cardiac malformations.
Discussion
As demonstrated in previous studies by
Dawson et al. (12), a significantly increased
incidence ofcardiac defects as compared to
controls occurred when the parent com-
pounds TCE and DCE were administered
in a similar rat model. This study also
demonstrated that exposure to TCAA, a
major metabolite ofTCE, administered in
drinking water resulted in increased num-
bers ofimplantation and resorption sites
and selective cardiac teratogenicity.
The logic for our initial dose selection
was based on the highest possible level of
the metabolite that would be expected to be
produced from the breakdown ofthe maxi-
mum TCE dose tested (1100 ppm) (11).
The drinking-water dose ofTCAA given in
this study (291 mg/kg/day) was similar to
that administered bygavage (330 mg/kg/day
TCAA) by Smith et al. (13). At levels of
330 mg/kg/day and above in the Smith et
al. (13) study, a dose-dependent increase in
implantation sites and resorption sites and
an increase in frequency ofsoft-tissue mal-
formations (mainly cardiovascular) occurred.
Similar effects were observed for the dosage
ofTCAAused in this study.
The types ofcardiac defects produced in
this study (Table 2) are consistent with
those in our previous reports (9-11) and
those reported in the human epidemiology
study by Goldberg et al. (8). The variety of
defects found showed no particular lesion,
grouping, orsyndrome predominating. The
defects observed in this study are different
from those reported by Smith et al. (13) in
which the Long-Evans rat model used
reported mainly malalignment ventricular
septal defects. Their method ofexamining
fetuses was by section microscopy, which is
quite different from the dissection method
used in this study. Our dissection method
is more sensitive for lesions such as adhered
valve cusps, separating oval fossa defects
from true secundum atrial defects, and
detection ofabnormal valve dimensions.
Until the mechanism for these diverse car-
diac defects is determined, it is difficult to
speculate on why there is no predominance
of one type of lesion. The authors are
currentlystudying these mechanisms.
Although it is accepted that "no animal
test and battery oftests will provide com-
plete assurance in the prediction ofhuman
teratologic risk" (27), the similarities in the
timing and sequencing of events during
crucial periods of embryogenesis and
organogenesis (particularly cardiogenesis)
between humans and rats suggest that the
rat is a suitable nonprimate choice for
studying teratogenic effects on developing
fetuses (27-34). The Sprague-Dawley rat
model was specifically selected because of
the very low incidence ofspontaneous car-
diovascular anomalies (35,36) and the gen-
eral similarity to the human incidence and
types ofspontaneous cardiac abnormalities
occurring (27-30). All these factors con-
tribute to the potential importance ofthese
findings and their possible application to
the human situation.
It was not within the scope of these
studies to determine the mechanisms respon-
sible for these defects, but rather the inci-
dence and types ofcardiacdefects that occur.
Other limitations ofthis project indude cer-
tain cardiac and great vessel abnormalities
that may have gone undetected, such as
coarctation ofthe aorta, regurgitant valves,
and abnormal coronary artery distribution
beyond the ostium. It was also not possible
to substantiate delivery ofcompounds to the
fetal tissue because ofsensitivity limitations
ofour gas chromatography methods. Failure
to demonstrate cardiac defects associated
with other metabolites in this study may be
due to their lack ofteratogenesis or their
inability to cross the fetal membranes and/or
the rapid clearance of those compounds
from thematernal body.
Dose response was not an aim of these
studies and the doses used were higher than
those typically found in contaminated wells
and water supplies. The high levels used in
these studies may be above a threshold level
and thus the similar levels ofheart defects
found at the low and high levels for both
TCE and DCE. Without knowing dose
response and the mechanism, it would be
difficult to comment on this apparent simi-
lar level ofresponse. Further studies to look
at dose-response trends and at the possible
mechanisms involved are ongoing.
It is also recognized by the investigators
that there are many routes and com-
binations of those routes ofexposure to
contaminated water-drinking water con-
sumption, inhalation, and dermal expo-
sure-but because ofthe constraints ofthe
research study, only drinking water con-
sumption was studied at this time. When all
possible routes ofexposure are considered
the actual dose or concentration ofexposure
may in fact be higher than that with drink-
ing-water exposure alone. A dose-response
studyis currentlybeingcompleted.
The low number of cardiac defects
found in non-TCAA, TCE, or DCE groups
does not predude the cardiac teratogenicity
ofthese metabolites, but rather demon-
strates that an increase could notbe detected
at the power level we used. The findings of
the study do not prove that human cardiac
defects are caused byTCE, DCE, orTCAA;
however, these studies raise awareness ofthe
potential cardiac teratogenicity of some
halogenated compounds.
These data demonstrate that when
TCE, DCE, or TCAA in the doses studied
are administered in drinking water to a
pregnant rat, specific fetal cardiac terato-
genicity occurs. TCAA also results in an
increased number of implantation and
resorption sites as compared to the control
animals. These data therefore support the
hypothesis that not only TCE and DCE,
the parent compounds, but also a meta-
bolic breakdown product may cause selec-
tive cardiac teratogenesis in a mammalian
model. Detailed reports have been or will
be published (11,12,25).
Experimental studies discussed here
cannot be extrapolated directly to humans,
although many processes ofcell division,
migration, and differentiation are common
to all mammals during gestation. Thus it is
anticipated that further investigation may
elucidate mechanisms relating gestational
exposure to specific halogenated hydro-
carbons and congenital cardiac defects.
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